ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

efinopegdutide

Also written as “Efinopegdutide”, “JNJ-64565111” and “JNJ-64565111 Dose Level 1”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Obesity · Diabetes Mellitus, Type 2 · Kidney Failure, Chronic, led by 2 companies.

Drug pageEfinopegdutide: every studyAll 15 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Mar 23, 201815 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson80 open or runningphase 2since Mar 23, 2018Jun 24, 2016none ahead
Merckits history only70 open or runningphase 2since Jun 28, 2021Jun 28, 2021none ahead
  • Named in Merck’s own pipeline as efinopegdutide (MK-6024), phase 2, as of Nov 2, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 24, 2016First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT02862431 · 24 enrolled · Germany
  2. Jul 28, 2017Phase 1 study in Diabetes Mellitus, Type 2NCT03235219 · 39 enrolled · United States
  3. Dec 9, 2017Named efinopegdutideINNProposed as its International Nonproprietary Name in WHO's List 118 · before, JNJ-64565111
  4. Mar 23, 2018Phase 2 study in ObesityNCT03486392 · 474 enrolled · United States, Belgium, Canada and more
  5. May 23, 2018Phase 1 study in Kidney Failure, ChronicNCT03546205 · 40 enrolled · United States
  6. Jun 22, 2018Phase 2 study in ObesityNCT03586830 · 196 enrolled · United States
  7. Jun 29, 2018Phase 1 study in ObesityNCT03586843 · 52 enrolled · United States
  8. Jul 10, 2018Phase 1 study in HealthyNCT03606057 · 188 enrolled · United States
  9. Aug 2, 2018Phase 1 study in HealthyNCT03618160 · 42 enrolled · Japan

TargetBeta

“A synthetic peptide of oxyntomodulin conjugated to the constant region of human immunoglobulin G4 (IgG4) and dual glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist, with potential weight reducing and anti-diabetic activities and that may potentially be used for the treatment of non-alc…”NCIt, read by Claude
“Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
UBT251The United Laboratories Internationalphase 312
DR10624ruleHuadong Medicinephase 36
AZD9550AstraZenecaphase 27
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

All 8 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03618160Healthy · Japan1TerminatedJun 21, 201942
NCT03606057Healthy · United States1CompletedFeb 8, 2019188
NCT03586843Obesity · United States1CompletedMar 17, 201952
NCT03586830Obesity · United States2CompletedApr 5, 2019196
NCT03546205Kidney Failure, Chronic · United States1CompletedDec 17, 201840
NCT03486392Obesity · United States, Belgium, Canada and more2CompletedMar 8, 2019474
NCT03235219Diabetes Mellitus, Type 2 · United States1CompletedFeb 19, 201839
NCT02862431Diabetes Mellitus, Type 2 · Germany1TerminatedNov 29, 201624

How it is read

Names in the registry

  • “Efinopegdutide”, 6 entries
  • “JNJ-64565111”, 6 entries
  • “JNJ-64565111 Dose Level 1”, 2 entries
  • “JNJ-64565111 Dose Level 2”, 2 entries
  • “JNJ-64565111 Dose Level 3”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.